San Francisco Leading the Way in STI Prevention with New Drug Recommendation
San Francisco has taken a proactive approach to tackling the rising rates of sexually transmitted infections (STIs) by recommending the use of a new drug called DoxyPEP in high-risk communities. DoxyPEP involves taking a single 200 mg dose of the antibiotic doxycycline within 72 hours of a sexual encounter to minimize the chances of acquiring STIs.
According to recent data, approximately 40% of individuals who are already taking Pre-Exposure Prophylaxis (PrEP) in San Francisco have also tried DoxyPEP as an additional measure for STI prevention. The results presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2024 showed a promising 58% decrease in STIs among those taking DoxyPEP in San Francisco.
Experts have welcomed the results from San Francisco and other trials, which have shown a reduction in STIs among gay men. However, a trial conducted in Kenya revealed that DoxyPEP was less effective in reducing chlamydia levels.
Jorge Roman, a representative from the San Francisco AIDS Foundation, praised the study results and described DoxyPEP as an exciting new tool for STI prevention. He emphasized the importance of continuing research and investigation into the effectiveness of DoxyPEP in various populations.
As San Francisco leads the way in recommending DoxyPEP for STI prevention, other cities and countries are likely to consider incorporating this drug as part of their public health strategies. The promising results from these trials highlight the potential impact of DoxyPEP in reducing the spread of STIs and safeguarding the health of high-risk communities.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”